Wang Y, Bahar M, Jansen A, Kocks J, Alffenaar J, Hak E
J Antimicrob Chemother. 2019; 74(10):2848-2864.
PMID: 31127283
PMC: 6814093.
DOI: 10.1093/jac/dkz221.
Nahid P, Dorman S, Alipanah N, Barry P, Brozek J, Cattamanchi A
Clin Infect Dis. 2016; 63(7):e147-e195.
PMID: 27516382
PMC: 6590850.
DOI: 10.1093/cid/ciw376.
Navid A, Ng D, Wong S, Lightstone F
CPT Pharmacometrics Syst Pharmacol. 2016; 5(2):74-81.
PMID: 26933518
PMC: 4761233.
DOI: 10.1002/psp4.12061.
Ito K, Chiba K, Horikawa M, Ishigami M, Mizuno N, Aoki J
AAPS PharmSci. 2003; 4(4):E25.
PMID: 12645997
PMC: 2751314.
DOI: 10.1208/ps040425.
Yew W
Drug Saf. 2002; 25(2):111-33.
PMID: 11888353
DOI: 10.2165/00002018-200225020-00005.
Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.
Pea F, Furlanut M
Clin Pharmacokinet. 2001; 40(11):833-68.
PMID: 11735605
DOI: 10.2165/00003088-200140110-00004.
Absence of effect of rufloxacin on theophylline pharmacokinetics in steady state.
Kinzig-Schippers M, Fuhr U, Cesana M, Muller C, STAIB A, Rietbrock S
Antimicrob Agents Chemother. 1998; 42(9):2359-64.
PMID: 9736563
PMC: 105833.
DOI: 10.1128/AAC.42.9.2359.
Influence of a newly developed quinolone, T-3761, on pharmacokinetics of theophylline in rats.
Hasegawa T, Nadai M, Haghgoo S, Yamaki K, Takagi K, Nabeshima T
Antimicrob Agents Chemother. 1995; 39(9):2138-40.
PMID: 8540732
PMC: 162897.
DOI: 10.1128/AAC.39.9.2138.
Quinolones potentiate cefazolin-induced seizures in DBA/2 mice.
DE Sarro A, Zappala M, Chimirri A, Grasso S, De Sarro G
Antimicrob Agents Chemother. 1993; 37(7):1497-503.
PMID: 8395790
PMC: 188001.
DOI: 10.1128/AAC.37.7.1497.
Clinical pharmacokinetics of sparfloxacin.
Shimada J, Nogita T, Ishibashi Y
Clin Pharmacokinet. 1993; 25(5):358-69.
PMID: 8287631
DOI: 10.2165/00003088-199325050-00002.
Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly.
Wiseman L, Balfour J
Drugs Aging. 1994; 4(2):145-73.
PMID: 8186542
DOI: 10.2165/00002512-199404020-00007.
The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects.
Batty K, Davis T, Ilett K, Dusci L, Langton S
Br J Clin Pharmacol. 1995; 39(3):305-11.
PMID: 7619673
PMC: 1365008.
DOI: 10.1111/j.1365-2125.1995.tb04453.x.
Effect of norfloxacin on theophylline pharmacokinetics at steady state.
Bowles S, Popovski Z, Rybak M, Beckman H, Edwards D
Antimicrob Agents Chemother. 1988; 32(4):510-2.
PMID: 3377462
PMC: 172211.
DOI: 10.1128/AAC.32.4.510.
Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Monk J, Price A, Benfield P, Todd P, Ward A
Drugs. 1988; 35(4):373-447.
PMID: 3292209
DOI: 10.2165/00003495-198835040-00003.
Predicting the ciprofloxacin-theophylline interaction from single plasma theophylline measurements.
Bachmann K, SCHWARTZ J, Jauregui L
Br J Clin Pharmacol. 1988; 26(2):191-4.
PMID: 3207556
PMC: 1386528.
DOI: 10.1111/j.1365-2125.1988.tb03387.x.
Inhibition of drug metabolism by quinolone antibiotics.
Edwards D, Bowles S, Svensson C, Rybak M
Clin Pharmacokinet. 1988; 15(3):194-204.
PMID: 3052987
DOI: 10.2165/00003088-198815030-00004.
Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.
Segev S, Rehavi M, Rubinstein E
Antimicrob Agents Chemother. 1988; 32(11):1624-6.
PMID: 2855295
PMC: 175940.
DOI: 10.1128/AAC.32.11.1624.
Effect of norfloxacin on theophylline metabolism.
Davis R, Kelly H, Quenzer R, Standefer J, Steinberg B, Gallegos J
Antimicrob Agents Chemother. 1989; 33(2):212-4.
PMID: 2719466
PMC: 171459.
DOI: 10.1128/AAC.33.2.212.
Fluoroquinolone antimicrobial agents.
Wolfson J, Hooper D
Clin Microbiol Rev. 1989; 2(4):378-424.
PMID: 2680058
PMC: 358131.
DOI: 10.1128/CMR.2.4.378.
Effect of lomefloxacin on theophylline pharmacokinetics.
Nix D, Norman A, Schentag J
Antimicrob Agents Chemother. 1989; 33(7):1006-8.
PMID: 2675751
PMC: 176053.
DOI: 10.1128/AAC.33.7.1006.